Stories related to Innovation

Roche results for half-year 2019

When everyday counts, data makes a meaningful difference for patients

A conversation with Roland Beckmann, inventor of the DutaMab technology

Interview with Dutalys co-founder and inventor of the DutaMab technology platform, Roland Beckmann, on his invention and journey founding a biotech.

Scaling up cancer care

Personalised healthcare is becoming a reality across the continuum of cancer care, from the nanoscale to the national.

Partnering to drive innovation in cancer immunotherapy

We’re partnering with many different stakeholders to find the most effective way for the immune system to identify and kill cancer cells.

Our philanthropic journey

Over 100 years of partnerships to make a sustainable difference for communities in which we operate and beyond.

Our response to cancer always starts with the science

Targeting cancer demands a deep understanding of its complexities. Our researchers have the freedom to explore cutting-edge science & technology to achieve this.

Tumour-agnostic treatments: A radical new approach to tackling cancer

Learn how tumour-agnostic approaches have the potential to change the way we diagnose, and treat, cancer in the future.

An introduction to personalised healthcare for the eye

Insights on how personalised healthcare can bring meaningful benefits to patients with retinal diseases

Getting closer to cancer research's holy grail

Combining clinical and genomic data to advance personalised healthcare.

Measuring what matters

How Patient-Reported Outcomes are helping to redefine haemophilia care

Measuring what matters

How Patient-Reported Outcomes are helping to redefine haemophilia care

What is Personalised Healthcare?

Personalised healthcare is about providing the right treatment for the right patient. Fitting treatments to patients has always been the objective of medicine, of course. But only recent advances in science and technology have made this possible.

Elevating the patient voice in Huntington’s disease

How patient partnership is shaping the future of research and clinical development for Huntington’s disease.

Partnering to fulfill the promise of personalised healthcare

The promise of personalised healthcare is a simple one: finding the right treatment for every patient. Through strategic partnerships, Roche is committed to fulfilling that promise.

Will the future be feminine?

Betsy Leatherman talks about leadership characteristics that are said to be “female” and what this means for the future.

Will quantum computers solve the problems of the future?

Martin Strahm talks about the idea, the potential and the limitations of quantum computers.

Will genomics revolutionise the future of medicine?

Joanne Hackett talks about genomics, healthcare, big data and people’s hesitation to share medical data.

Hepatitis B - Aiming for cure of a killer

Hepatitis B is responsible for more than 800,000 deaths a year. Roche is working on a cure.

How decades of blood cancer research is paying off

We explore how a growing understanding of the biology of blood cancers is transforming the development and delivery of treatments for patients.

A boon for biotech

Our local partners are helping to shape the future of healthcare.

Open-sourcing health

Effective and purposeful collaborations will allow us to do much more together, to be much smarter together, than we can be alone.

Roche at ESMO 2018

Fighting cancer together, one patient at a time.

Supporting people with MS: A nurse’s story

Learn how specialist MS nurse Anna Cunningham, helps people with MS manage their condition

Beating lung cancer – one gene at a time

How gene targeting might transform the lives of patients with rare forms of lung cancer

Roche at WCLC 2018

Understanding lung cancer, strand by strand

Striking back at stroke risk

Why less is more in atrial fibrillation management

The patient as partner

Empowered patients are redefining the healthcare environment on their own terms.

‘Accelerators and brakes’ to restore immune balance

Roche strategy in Immunology is to make use of the growing scientific understanding of immune pathways and to selectively manipulate these in order to restore immune balance.

The NT-proBNP Story

Biomarkers play a crucial role in Roche’s commitment to personalised healthcare. To find them, we rely on the promising research of our external partners.

Partnering to improve cancer care in the Middle East

Peter Hug, Head of Roche Pharma EEMEA Region shares his perspective on partnering to solve cancer challenges in emerging markets.

Progress in haemophilia: a personal perspective

The haemophilia community is united and strong. Find out more about the haemophilia community and progress being made in the field from Brian O’Mahony, Chief Executive of the Irish Haemophilia Society.

Sustainability at Roche: Our impact

Engaging with stakeholders is crucial to create sustainable value. Stakeholder engagement enables us to jointly develop solutions.

Better together: Helping one million people with diabetes

Ask anybody with diabetes: managing it is time consuming, exhausting and very annoying.

Of bonds and benefits

Two made-in-Japan collaborations strengthen both Roche and its partners.

Highlights Annual Report 2017

Read the incredible stories behind the numbers.

Roche at J.P. Morgan Healthcare Conference

Collaborating to drive the future of personalised healthcare

Rising to the challenge

As multidrug resistant strains of bacteria are posing a growing threat to human health worldwide, our scientists are working hard on the next generation of antibiotics and diagnostic tests.

The value of diagnostics in heart failure management

Heart failure affects millions of people and despite improvement in care, management remains challenging. Biomarkers can help patients at every stage of care.

Integrated, connected laboratories: a new era in lab testing

A new era in lab testing is tackling today’s challenges and tomorrow’s needs in a rapidly shifting global health landscape.

Changing the perspective on lung cancer: a story of hope and survival

How does understanding each lung cancer’s unique footprint set you on the right path for a promising new future? Find out...

MS measurements explained

How we define the ways in which multiple sclerosis can be measured.

Keeping every drop safe

Screening tests protect blood supplies from contamination by the Zika virus.

The realities of pursuing the cure for cancer

Cindy Perettie, our Global Head of Oncology Strategy, provides her personal perspective on the challenges of leading the cure for cancer.

Smart technology speeds up development of antibiotics

Roche and British biotechnology company Discuva are collaborating to develop new classes of antibiotics for the treatment of multidrug-resistant bacteria.

Fighting antimicrobial resistance with diagnostics

Antimicrobial resistance is a global and continuously raising global health challenge. Here’s what we are doing to address this problem.

A new strategy for cervical cancer prevention

Learn how new screening, triage and diagnostic tests help clinicians decide which women to treat for cervical cancer.

Organs-on-a-Chip technology

Tiny labs made of plastic simulate the human body- the Organs-on-a-Chip technology shows new approaches to obtain human-relevant information on a potential drug.

Annual Report 2016 highlights

Creating value through partnerships

Partnering builds on our culture, one in which we listen to a potential partner and structure a collaboration that meets both parties’ needs.

No woman needs to die from cervical cancer

Despite being highly preventable through screening,treatment and vaccination, cervical cancer remains one of the most common and deadly women’s cancer.

Spotlight on comprehensive genomic profiling

Comprehensive genomic profiling provides valuable information that can help determine the best possible treatment for each patient.

Annual Report 2015 highlights

A quick journey through Roche’s business year at a glance.

A new era in cancer diagnostics: a personal perspective

Dr Walter Koch, Head of Research at Roche Molecular Diagnostics, explains how his “dream job” is helping push into new frontiers of science.

How Roche Partnering succeeds in the quest for innovation

Excellence in science

In our pursuit of excellence in science, our distinctiveness rests on four key elements: an exceptionally broad and deep understanding of molecular biology, the seamless integration of our pharmaceuticals and diagnostics capabilities, a diversity of approaches to maximise innovation, and a long-term orientation.

“It was a dream come true to have such a direct impact on women’s health.”

Catherine, a trained gynecologist, who is passionate about women’s health shares why she joined Roche to work on a cervical cancer test.

To understand biology, you need to be able to measure it.

A biomarker model that is almost 100% predictive

Breast cancer: Know more

Despite the significant progress made over the last few decades in patient outcomes, breast cancer is still the most common cancer affecting women.

What's the prognosis for diagnostic testing in lung cancer?

Being able to test biopsy tissue for all of the targeted therapies being developed is rapidly becoming a significant practical challenge - Roche Group is working on innovative solutions.

Keeping cancer immunotherapy personal

Fighting cancer using patients own immune system is a concept that has been around for a long time, and real advances in our understanding about how to do this have been made over the last 10-15 years.

Personalised healthcare inconceivable without biomarkers

In addition to promoting an exchange of expertise, the main goal of the Oncology Biomarker Symposium was to grow a network across functions, divisions and geographic sites. Biomarker tests can only parallel drug development and, ideally, be launched alongside treatments if Pharmaceuticals and Diagnostics work closely together.

Small efforts make a difference in the fight against cancer

February 4 was World Cancer Day. Just another day in the calendar! Not really, if you consider that it is a reminder of the fact that an estimated 13 million plus new cases occur every year